News › Pharma  ·  25 May 2026, 4:46 PM IST  ·  3 months ago

Harikanta Overseas IPO 50% Subscribed: SME Listing Watch

Bias: Mildly Bullish +2675% confidencePharmaSme IPO

In one line — Neutral to slightly positive for the IPO; wait for final subscription data and GMP for a clearer picture.

Bearish
Bullish
−1000+26+100

Source: Mint · AI-summarised by Anadi · Updated 25 May 2026, 5:38 PM IST

Pharmawatching
Sme IPOwatching

What Happened

The Harikanta Overseas IPO, valued at ₹24.30 crore, has been booked over 50% by Day 4. It is entirely a fresh issue of 0.27 crore shares, priced between ₹86 to ₹91 apiece, meaning all proceeds will go directly to the company.

Why It Matters (for you)

The subscription status of an IPO, especially for an SME, is a key indicator of investor demand and potential listing performance. A fresh issue structure is generally positive as it implies the company is raising capital for its own growth and expansion, rather than existing shareholders selling their stake.

Impact on Indian Markets

As an SME IPO, the direct market impact on the broader NSE/BSE indices is minimal. However, for investors interested in the SME segment, the subscription level provides insight into the demand for Harikanta Overseas. A moderate subscription suggests cautious but present investor interest. The listing performance will be crucial for early investors.

What Traders Should Watch Next

Traders should closely watch the final subscription figures on the last day of the IPO. The Grey Market Premium (GMP) can also offer a speculative indication of listing gains. Post-listing, monitor the stock's price action and trading volumes to assess investor confidence and liquidity in the secondary market.

Key Evidence

  • Harikanta Overseas IPO booked over 50% by Day 4.
  • IPO worth ₹24.30 crore, entirely a fresh issue of 0.27 crore shares.
  • Priced in the range of ₹86 to ₹91 apiece.
  • All proceeds will be received by the company.
  • Risk flag: Lower liquidity in SME segment post-listing